Zoledronic acid significantly enhances radiation-induced apoptosis against human fibrosarcoma cells by inhibiting radioadaptive signaling

International Journal of Oncology

Volumn 42, Issue 2, 2013, Pages 525-534

  Koto, Kazutaka ^a   Murata, Hiroaki ^a,b   Kimura, Shinya ^c   Sawai, Yasushi ^a   Horie, Naoyuki ^a   Matsui, Takaaki ^a   Ryu, Kazuteru ^a   Ashihara, Eishi ^d   Maekawa, Taira ^d   Kubo, Toshikazu ^a   Fushiki, Shinji ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b MATSUSHITA MEMORIAL HOSPITAL   (Japan)

^c SAGA UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Combined effects; Fibrosarcoma; Radiation; Reactive oxygen species; Zoledronic acid

Indexed keywords

ACETYLCYSTEINE; CASPASE; CASPASE INHIBITOR; GUANOSINE TRIPHOSPHATASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BAD; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FIBROSARCOMA; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PRENYLATION; RADIOSENSITIVITY; SARCOMA CELL; SEQUENTIAL ANALYSIS; SOFT TISSUE SARCOMA; X IRRADIATION;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; DIPHOSPHONATES; FIBROSARCOMA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; RADIATION, IONIZING; REACTIVE OXYGEN SPECIES;

EID: 84873659875     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1735     Document Type: Article

References (50)

1. Pritchard DJ, Sim FH, Ivins JC, Soule EH and Dahlin DC: Fibrosarcoma of bone and soft tissues of the trunk and extremities. Orthop Clin North Am 8: 869-881, 1977.
2. Pritchard DJ, Soule EH, Taylor WF and Ivins JC: Fibrosarcoma - a clinicopathologic and statistical study of 199 tumors of the soft tissues of the extremities and trunk. Cancer 33: 888-897, 1974.
3. Scott SM, Reiman HM, Pritchard DJ and Ilstrup DM: Soft tissue fibrosarcoma. A clinicopathologic study of 132 cases. Cancer 64: 925-931, 1989.
4. Russell RG and Rogers MJ: Bisphosphonates: from the laboratory to the clinic and back again. Bone 25: 97-106, 1999.
5. Green JR: Antitumor effects of bisphosphonates. Cancer 97: 840-847, 2003.
6. Lee MV, Fong EM, Singer FR and Guenette RS: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61: 2602-2608, 2001.
7. Kubo T, Shimose S, Matsuo T, et al: Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells. J Orthop Res 24: 1138-1144, 2006.
8. Koto K, Murata H, Kimura S, et al: Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents. Oncol Rep 24: 233-239, 2010.
9. Horie N, Murata H, Nishigaki Y, et al: The third-generation bisphosphonates inhibit proliferation of murine osteosarcoma cells with induction of apoptosis. Cancer Lett 238: 111-118, 2006.
10. Horie N, Murata H, Kimura S, et al: Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma. Br J Cancer 96: 255-261, 2007.
11. Koto K, Horie N, Kimura S, et al: Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model. Cancer Lett 274: 271-278, 2009.
12. Jagdev SP, Coleman RE, Shipman CM, Rostami HA and Croucher PI: The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84: 1126-1134, 2001.
13. Kubo T, Shimose S, Matsuo T, Sakai A and Ochi M: Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells. Cancer Chemother Pharmacol 62: 111-116, 2008.
14. Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE and Holen I: Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 100: 1167-1178, 2008.
15. Ural AU, Avcu F, Candir M, Guden M and Ozcan MA: In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells. Breast Cancer Res 8: R52, 2006.
16. Algur E, Macklis RM and Hafeli UO: Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines. Int J Radiat Oncol Biol Phys 61: 535-542, 2005.
17. Milas L, Hunter NR, Mason KA, Kurdoglu B and Peters LJ: Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res 54: 3506-3510, 1994.
18. Tishler RB, Geard CR, Hall EJ and Schiff PB: Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 52: 3495-3497, 1992.
19. Acharya A, Das I, Chandhok D and Saha T: Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid Med Cell Longev 3: 23-34, 2010.
20. Sedelnikova OA, Redon CE, Dickey JS, Nakamura AJ, Georgakilas AG and Bonner WM: Role of oxidatively induced DNA lesions in human pathogenesis. Mutat Res 704: 152-159, 2010.
21. Ahmed KM and Li JJ: NF-kappa B-mediated adaptive resistance to ionizing radiation. Free Radic Biol Med 44: 1-13, 2008.
22. Hansen MB, Nielsen SE and Berg K: Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119: 203-210, 1989.
23. Ram R, Uziel O, Eldan O, et al: Ionizing radiation up-regulates telomerase activity in cancer cell lines by post-translational mechanism via ras/phosphatidylinositol 3-kinase/Akt pathway. Clin Cancer Res 15: 914-923, 2009.
24. Zingg D, Riesterer O, Fabbro D, Glanzmann C, Bodis S and Pruschy M: Differential activation of the phosphatidylinositol 3'-kinase/Akt survival pathway by ionizing radiation in tumor and primary endothelial cells. Cancer Res 64: 5398-5406, 2004.
25. Wang CY, Mayo MW and Baldwin AS Jr: TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274: 784-787, 1996.
26. Ryu K, Murata H, Koto K, et al: Combined effects of bisphosphonate and radiation on osteosarcoma cells. Anticancer Res 30: 2713-2720, 2010.
27. Morgan WF and Murnane JP: A role for genomic instability in cellular radioresistance? Cancer Metastasis Rev 14: 49-58, 1995.
28. Morgan WF: Is there a common mechanism underlying genomic instability, bystander effects and other nontargeted effects of exposure to ionizing radiation? Oncogene 22: 7094- 7099, 2003.
29. Ch'ang HJ, Maj JG, Paris F, et al: ATM regulates target switching to escalating doses of radiation in the intestines. Nat Med 11: 484-490, 2005.
30. Stecca C and Gerber GB: Adaptive response to DNA-damaging agents: a review of potential mechanisms. Biochem Pharmacol 55: 941-951, 1998.
31. Spitz DR, Azzam EI, Li JJ and Gius D: Metabolic oxidation/ reduction reactions and cellular responses to ionizing radiation: a unifying concept in stress response biology. Cancer Metastasis Rev 23: 311-322, 2004.
32. Schieven GL, Kirihara JM, Myers DE, Ledbetter JA and Uckun FM: Reactive oxygen intermediates activate NF-kappa B in a tyrosine kinase-dependent mechanism and in combination with vanadate activate the p56lck and p59fyn tyrosine kinases in human lymphocytes. Blood 82: 1212-1220, 1993.
33. Guo G, Wang T, Gao Q, et al: Expression of ErbB2 enhances radiation-induced NF-kappaB activation. Oncogene 23: 535-545, 2004.
34. Blonska M, You Y, Geleziunas R and Lin X: Restoration of NF-kappaB activation by tumor necrosis factor alpha receptor complex-targeted MEKK3 in receptor-interacting proteindeficient cells. Mol Cell Biol 24: 10757-10765, 2004.
35. Chen G and Goeddel DV: TNF-R1 signaling: a beautiful pathway. Science 296: 1634-1635, 2002.
36. Dent P, Yacoub A, Fisher PB, Hagan MP and Grant S: MAPK pathways in radiation responses. Oncogene 22: 5885-5896, 2003.
37. Tang G, Minemoto Y, Dibling B, et al: Inhibition of JNK activation through NF-kappaB target genes. Nature 414: 313-317, 2001.
38. Chen X, Shen B, Xia L, et al: Activation of nuclear factor kappaB in radioresistance of TP53-inactive human keratinocytes. Cancer Res 62: 1213-1221, 2002.
39. Kim IA, Bae SS, Fernandes A, et al: Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res 65: 7902-7910, 2005.
40. Toulany M, Kasten-Pisula U, Brammer I, et al: Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Clin Cancer Res 12: 4119-4126, 2006.
41. Toulany M, Kehlbach R, Florczak U, et al: Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Ther 7: 1772-1781, 2008.
42. Mandic A, Viktorsson K, Heiden T, Hansson J and Shoshan MC: The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis. Melanoma Res 11: 11-19, 2001.
43. Smalley KS and Eisen TG: Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects. Int J Cancer 98: 514-522, 2002.
44. Spry M, Scott T, Pierce H and D'Orazio JA: DNA repair pathways and hereditary cancer susceptibility syndromes. Front Biosci 12: 4191-4207, 2007.
45. Cooke MS, Evans MD, Dizdaroglu M and Lunec J: Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J 17: 1195-1214, 2003.
46. Dhar A, Young MR and Colburn NH: The role of AP-1, NF-kappaB and ROS/NOS in skin carcinogenesis: the JB6 model is predictive. Mol Cell Biochem 234-235: 185-193, 2002.
47. Hunt CR, Sim JE, Sullivan SJ, et al: Genomic instability and catalase gene amplification induced by chronic exposure to oxidative stress. Cancer Res 58: 3986-3992, 1998.
48. Wong GH: Protective roles of cytokines against radiation: induction of mitochondrial MnSOD. Biochim Biophys Acta 1271: 205-209, 1995.
49. Pommier Y, Barcelo JM, Rao VA, et al: Repair of topoisomerase I-mediated DNA damage. Prog Nucleic Acid Res Mol Biol 81: 179-229, 2006.
50. Sordet O, Redon CE, Guirouilh-Barbat J, et al: Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks. EMBO Rep 10: 887-893, 2009.